secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unicycive Therapeutics, Inc. (UNCY)
CIK:        0001766140
Form:       8-K
Filed at:   2026-09-28T20:31:05+00:00
Accession:  0001213900-26-104076
Event type: litigation
Sentiment:  negative
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Unicycive Therapeutics faces securities class action over oxylanthanum carbonate NDA statements
--------------------------------------------------------------------------------

- Securities class action filed Sept 3, 2026 in the U.S. District Court for the Northern District of California against Unicycive and certain officers.
- Lawsuit alleges federal securities law violations tied to public statements about the new drug application for oxylanthanum carbonate phosphate binder.
- The drug targets hyperphosphatemia in chronic kidney disease patients on dialysis; Unicycive calls the claims meritless and vows vigorous defense.
- Report signed Sept 28, 2026 by CFO John Townsend; UNCY common stock trades on Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766140/000121390026104076/0001213900-26-104076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766140/000121390026104076/ea0306890-8k_unicycive.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-104076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer